Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
Title: | Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan |
Other Titles: | Confirmation of the 8th edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan |
Authors: | Mizumachi, Takatsugu Browse this author →KAKEN DB | Homma, Akihiro Browse this author →KAKEN DB | Sakashita, Tomohiro Browse this author →KAKEN DB | Kano, Satoshi Browse this author →KAKEN DB | Hatakeyama, Hiromitsu Browse this author →KAKEN DB | Fukuda, Satoshi Browse this author →KAKEN DB |
Keywords: | AJCC/UICC TNM staging system | Head and neck cancer | Human papillomavirus | Oropharynx | p16 |
Issue Date: | Aug-2017 |
Publisher: | Springer |
Journal Title: | International journal of clinical oncology |
Volume: | 22 |
Issue: | 4 |
Start Page: | 682 |
End Page: | 689 |
Publisher DOI: | 10.1007/s10147-017-1107-0 |
PMID: | 28271391 |
Abstract: | Background: Several studies have demonstrated that the 7th edition of the AJCC/UICC TNM staging classification system does not consistently distinguish between prognostic subgroups for human papillomavirus (HPV)-mediated oropharyngeal squamous cell carcinoma (OPSCC). The 8th edition of the AJCC/UICC TNM staging came into effect for use with HPV-mediated OPSCC on or after January 1, 2017. This study confirms that the 8th edition of the AJCC/UICC TNM staging system for HPV- mediated OPSCC accurately reflects disease outcomes. Patients and methods:We retrospectively analyzed 195 patients with OPSCC treated at Hokkaido University Hospital, Sapporo, Japan between 1998 and 2015. HPV status was evaluated by immunohistochemical analysis of p16. Results: Of the 195 OPSCC patients, 111 (56.9%) were p16 positive, and 84 (43.1%) were p16 negative. The 3-year overall survival rate (OS) was significantly lower in the p16-negative patients with stage III-IV in comparison with those with stage I-II (55.0% vs 93.1%, p<0.01). The 3-year OS did not differ significantly between stage I-II and stage III-IV in the p16-positive patients (86.7% vs 87.7%). According to the 8th edition of the AJCC/UICC TNM staging system, stage I-II and stage III could be differentiated on the basis of the 3-year OS in the p16-positive patients (90.9% vs 70.2%, p<0.01). Conclusions: The 7th edition of the AJCC/UICC TNM staging system is suitable for use with p16-negative patients; however, it does not effectively discriminate between p16-positive patients. Therefore, the 8th edition of the AJCC/UICC TNM staging system is more suitable for HPV-mediated OPSCC in Japan. |
Rights: | This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-017-1107-0 |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/71138 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 水町 貴諭
|